BioGend Therapeutics Co., Ltd. (TPEX:6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
39.40
-1.60 (-3.90%)
Sep 19, 2025, 1:30 PM CST
-3.90%
Market Cap4.90B
Revenue (ttm)195.02M
Net Income (ttm)-127.10M
Shares Out124.26M
EPS (ttm)-1.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,200,965
Average Volume1,385,949
Open41.50
Previous Close41.00
Day's Range39.20 - 41.50
52-Week Range23.20 - 49.15
Beta0.14
RSI43.95
Earnings DateNov 7, 2025

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2024, BioGend Therapeutics's revenue was 167.65 million, an increase of 52.53% compared to the previous year's 109.91 million. Losses were -116.47 million, -25.49% less than in 2023.

Financial Statements

News

There is no news available yet.